Use of mechanical thrombectomy on qualifying stroke patients could result in major savings to the healthcare economy in the United Kingdom and other western countries with a similar healthcare structure, according to a new study presented at the Society of NeuroInterventional Surgery 12th Annual Meeting in San Francisco, USA.
In the last decade, intra-arterial stroke therapy (in which thrombolytic agents and devices are passed through the arteries directly to the clot site) has gained notable momentum as an effective and safe treatment option for patients. Two new studies released at the Society of NeuroInterventional Surgery 12th Annual Meeting (27–30 July, San Francisco, USA) further reinforce the value and progress of intra-arterial treatment and conclude that the new devices that facilitate this approach are reducing treatment times, improving outcomes and decreasing mortality rates.
The US FDA has approved the Reshape Integrated Dual Balloon System (ReShape). The system is a temporary weight-loss system of gastric balloons that are placed in a minimally invasive manner to occupy space in the stomach. They should be removed after six months.
Lombard Medical announced on 30 July 2015 the acquisition of Silicon Valley-based Altura Medical, a privately-held, venture-backed company that has developed an innovative ultra-low profile endovascular stent graft technology that, according to Lombard, offers a simple and predictable solution for the treatment of standard abdominal aortic aneurysm anatomies.
Eximo Medical has completed its series A funding round of US$1.6 million. Accelmed, a medical device Investment Fund, led the round, with the participation of the Alfred Mann Institute at the Technion (AMIT), the Technion R&D Foundation Ltd and a private investor.
Boston Childrens Hospital physicians report the first cases of children benefitting from 3D printing of their anatomy before undergoing high-risk brain procedures. The four children had life-threatening cerebrovascular malformations that posed special treatment challenges.
The US Centers for Medicare and Medicaid Services (CMS) has approved a new technology add-on payment for Bard’s Lutonix drug-coated balloon under the Medicare hospital inpatient prospective payment system.
Newly published research has documented the ability of Teleflex Incorporated’s Arrow central venous catheter (CVC) with ARROWg+ard Blue Technology to reduce both catheter-related bloodstream infections and direct costs associated with treating those infections, even when the infection risk is already low.
Gore has applauded the recent reclassification of endovascular abdominal aneurysm repair (EVAR) by the Centers for Medicare and Medicaid Services (CMS) to a new Medicare Severity Diagnosis-Related Group (MS-DRG) classification that will result in an increase in the hospital reimbursement for these procedures.
Patients with unresectable metastatic colorectal cancer (mCRC) that has spread only to the liver experienced the greatest improvement in progression-free survival in the liver from the addition of SIR-Spheres Y-90 resin microspheres to a current first-line chemotherapy regimen, according to new data from the SIRFLOX study presented at the European Society for Medical Oncology (ESMO) 17th World Congress of Gastrointestinal Cancer (WCGIC; 1–4 July, Barcelona, Spain).
Twelve-month results from the VeClose trial have demonstrated cyanoacrylate adhesive (CAE) is non-inferior to radiofrequency ablation (RFA) for the treatment of incompetent great saphenous veins.
After obtaining a PhD in Biophysics in London, UK, Janet Powell, professor of Vascular Biology & Medicine at Imperial College, London, studied medicine in the United States, before returning to the UK where she completed clinical training in pathology, specialising in cardiovascular risk. In this interview, Powell tells why the cause and management of abdominal aortic aneurysms are her major research interest and speaks about her early career, her mentors, the IMPROVE randomised controlled trial, and also her interests outside medicine.
David Cull, Greenville, USA, writes that vascular access placement in the elderly needs to take into account patients’ physiological age in an effort to predict survival.
Open vena caval surgery is rare. It is mainly performed for oncological indications when the inferior vena cava is involved by an adjacent tumour. One of the most common malignancies that affect the inferior vena cava is renal cell carcinomas of the kidneys with thrombi that extend into the inferior vena cava lumen or invade its wall. This occurs more commonly on the right side due to shorter renal vein. Removal of these tumors and accompanying thrombi provide survival benefits for those patients. Additionally, among the non-oncological indications of inferior vena cava surgery is the occasional need to remove inferior vena cava filters that have been inserted to prevent pulmonary emboli and could not be retrieved through conventional endovascular approaches.
Medtronic has announced that the first two European patient cases with the Endurant Evo AAA stent graft system were successfully performed by Hence Verhagen, chief of vascular surgery and his team at the Erasmus Medical Center in Rotterdam, the Netherlands.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos